Last Updated: November 13, 2026

Viatris Company Profile

« Back to Dashboard


What is the competitive landscape for VIATRIS

VIATRIS has twenty-eight approved drugs.

There are five US patents protecting VIATRIS drugs.

Summary for Viatris
US Patents:5
Tradenames:26
Ingredients:20
NDAs:28

Drugs and US Patents for Viatris

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viatris CARDURA XL doxazosin mesylate TABLET, EXTENDED RELEASE;ORAL 021269-001 Feb 22, 2005 RX Yes No ⤷  Start Trial ⤷  Start Trial
Viatris NITROSTAT nitroglycerin TABLET;SUBLINGUAL 021134-001 May 1, 2000 AB RX Yes No ⤷  Start Trial ⤷  Start Trial
Viatris NITROSTAT nitroglycerin TABLET;SUBLINGUAL 021134-002 May 1, 2000 AB RX Yes No ⤷  Start Trial ⤷  Start Trial
Viatris EDLUAR zolpidem tartrate TABLET;SUBLINGUAL 021997-001 Mar 13, 2009 AB RX Yes No 9,265,720 ⤷  Start Trial ⤷  Start Trial
Viatris CARDURA doxazosin mesylate TABLET;ORAL 019668-002 Nov 2, 1990 AB RX Yes No ⤷  Start Trial ⤷  Start Trial
Viatris EDLUAR zolpidem tartrate TABLET;SUBLINGUAL 021997-002 Mar 13, 2009 AB RX Yes Yes 9,597,281 ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Viatris

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viatris GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-002 Feb 5, 2001 6,150,366 ⤷  Start Trial
Viatris MUSE alprostadil SUPPOSITORY;URETHRAL 020700-001 Nov 19, 1996 5,242,391 ⤷  Start Trial
Viatris EPIPEN JR. epinephrine INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS 019430-002 Dec 22, 1987 8,048,035 ⤷  Start Trial
Viatris EPIPEN epinephrine INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS 019430-001 Dec 22, 1987 7,449,012 ⤷  Start Trial
Viatris CARDURA doxazosin mesylate TABLET;ORAL 019668-001 Nov 2, 1990 4,188,390 ⤷  Start Trial
Viatris EPIPEN epinephrine INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS 019430-001 Dec 22, 1987 8,048,035 ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for VIATRIS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe CapsulesInhalation Solution 0.02 mg/2 mL ➤ Subscribe 2009-01-21
➤ Subscribe Capsules 20 mg, 40 mg, 60 mg and 80 mg ➤ Subscribe 2005-02-07
➤ Subscribe Injection (Auto-injector) 0.15 mg/0.3 mL and 0.3 mg/0.3 mL ➤ Subscribe 2008-11-21
➤ Subscribe Inhalation Solution 300 mg/5 mL ➤ Subscribe 2009-06-29
➤ Subscribe Tablets 25 mg and 50 mg ➤ Subscribe 2004-11-19
➤ Subscribe Sublingual Tablets 5 mg and 10 mg ➤ Subscribe 2010-04-29
➤ Subscribe Sublingual Tablets 0.6 mg ➤ Subscribe 2011-12-29
➤ Subscribe Tablets 150 mg and 200 mg ➤ Subscribe 2005-11-09
➤ Subscribe Injection (Auto-injector) 0.15 mg/0.3 mL and 0.3 mg/0.3 mL ➤ Subscribe 2008-11-21
➤ Subscribe Nasal Spray 205.5 mcg/spray ➤ Subscribe 2011-12-15
➤ Subscribe Tablets 100 mg ➤ Subscribe 2004-10-25
➤ Subscribe Sublingual Tablets 0.3 mg, 0.4 mg and 0.6 mg ➤ Subscribe 2005-10-19

Supplementary Protection Certificates for Viatris Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2435025 2019C/532 Belgium ⤷  Start Trial PRODUCT NAME: UNE COMBINAISON DE GLYCOPYRROLATE (INCLUANT LES SELS ACCEPTABLES PHARMACEUTIQUEMENT, LES ESTERS, LES ENANTIOMERES OU LES AUTRES DERIVES DE CECI) ET DE FORMOTEROL (INCLUANT LES SELS ACCEPTABLES PHARMACEUTIQUEMENT, LES ESTERS, LES ENANTIOMERES OU LES AUTRES DERIVES DE CECI); AUTHORISATION NUMBER AND DATE: EU/1/18/1339 20181220
1280520 CA 2015 00017 Denmark ⤷  Start Trial PRODUCT NAME: TOBRAMYCIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/10/652/001-003 20110720
1214076 SZ 49/2008 Austria ⤷  Start Trial PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON
2435024 2190014-7 Sweden ⤷  Start Trial PRODUCT NAME: A COMBINATION OF FORMOTEROL INCLUDING ANY PHARMACEUUTICALLY ACCEPTABLE SALTS, ESTERS, OR SOLVATES THEREOF, GLYCOPYRROLATE INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, OR SOLVATES THEREOF, AND BUDESONIDE INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALT, ESTERS ORSOLVATES THEREOF; REG. NO/DATE: EU/1/20/1498 20201210
2515855 201740046 Slovenia ⤷  Start Trial PRODUCT NAME: COMBINATION OF GLYCOPYRRONIUM BROMIDE, FORMOTEROL OR ITS SALT AND BECLOMETASONE DIPROPIONATE; NATIONAL AUTHORISATION NUMBER: EU/1/17/1208/001-005; DATE OF NATIONAL AUTHORISATION: 20170717; AUTHORITY FOR NATIONAL AUTHORISATION: EU
0771217 CA 2006 00038 Denmark ⤷  Start Trial PRODUCT NAME: ETHINYLESTRADIOL (SOM BETA-CYCLODEXTRIN-CLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 38687 20060627; FIRST REG. NO/DATE: EU RVG 31781 20050804
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.